Home > Name List By 9 > 9-methyl-3-[(2-methylimidazol-1-yl)methyl]-2,3-dihydro-1H-carbazol-4-one Germany

CAS No 99614-02-5 , 9-methyl-3-[(2-methylimidazol-1-yl)methyl]-2,3-dihydro-1H-carbazol-4-one Search by region : Germany

  • Name: 9-methyl-3-[(2-methylimidazol-1-yl)methyl]-2,3-dihydro-1H-carbazol-4-one
  • Synonyms: PHL-ondansetron; Apo-ondansetron; Zofran ODT; Zophren; Novo-ondansetron; 99614-02-5;Zofran;9-methyl-3-[(2-methylimidazol-1-yl)methyl]-2,3-dihydro-1H-carbazol-4-one; PMS-ondansetron; Zudan;
  • CAS Registry Number:
  • Transport: UN 2811 6.1/PG 3
  • Melting Point: 231 - 232
  • Flash Point: 284 ºC
  • Boiling Point: 546 ºC at 760 mmHg
  • Density: 1.27 g/cm3
  • Safety Statements: S45-37/39-26
  • Hazard Symbols: T: Toxic;Xi: Irritant;
  • Flash Point: 284 ºC
  • Molecular Weight: 293.36296
  • InchiKey: FELGMEQIXOGIFQ-UHFFFAOYSA-N
  • InChI: InChI=1S/C18H19N3O/c1-12-19-9-10-21(12)11-13-7-8-16-17(18(13)22)14-5-3-
    4-6-15(14)20(16)2/h3-6,9-10,13H,7-8,11H2,1-2H3
  • Risk Statements: R25-36/37/38
  • Molecular Formula: C18H19N3O
  • Molecular Structure:CAS No:99614-02-5 9-methyl-3-[(2-methylimidazol-1-yl)methyl]-2,3-dihydro-1H-carbazol-4-one

Related products

Select to

99614-02-5; 116002-70-1 Ondansetron

  • Germany Aliapharm null
  • Tel: +49 69 971412-0
  • Fax: +49 69 971412-20
  • Address: AliaPharm GmbH Frankfurt Niedenau 49 60325 Frankfurt / Main null,nullGermany
Contact Supplier

Select to

1/1
References of 9-methyl-3-[(2-methylimidazol-1-yl)methyl]-2,3-dihydro-1H-carbazol-4-one
Title: Ondansetron
CAS Registry Number: 99614-02-5
CAS Name: 1,2,3,9-Tetrahydro-9-methyl-3-[(2-methyl-1H-imidazol-1-yl)methyl]-4H-carbazol-4-one
Molecular Formula: C18H19N3O
Molecular Weight: 293.36
Percent Composition: C 73.70%, H 6.53%, N 14.32%, O 5.45%
Literature References: Specific serotonin (5HT3) receptor antagonist. Prepn: I. H. Coates et al., EP 191562; eidem, US 4695578 (1986, 1987 both to Glaxo). Pharmacology: A. Butler et al., Br. J. Pharmacol. 94, 397 (1988). Clinical trials in cancer chemotherapy-induced nausea and vomiting: M. G. Kris et al., J. Clin. Oncol. 6, 659 (1988); L. Cubeddu et al., N. Engl. J. Med. 322, 810 (1990); M. Marty et al., ibid. 816. Clinical evaluation in treatment of bulimia: P. L. Faris et al., Lancet 355, 792 (2000); in early onset alcoholism: B. A. Johnson et al., J. Am. Med. Assoc. 284, 963 (2000). Review of pharmacology and therapeutic use: A. Markham, E. M. Sorkin, Drugs 45, 931-952 (1993); of clinical pharmacokinetics: K. H. Simpson, F. M. Hicks, J. Pharm. Pharmacol. 48, 774-781 (1996).
Properties: Crystals from methanol, mp 231-232°.
Melting point: mp 231-232°
 
Derivative Type: Hydrochloride dihydrate
CAS Registry Number: 99614-01-4
Manufacturers' Codes: GR-38032F; GR-C507/75; SN-307
Trademarks: Zofran (GSK); Zophren (GSK)
Molecular Formula: C18H19N3O.HCl.2H2O
Molecular Weight: 365.85
Percent Composition: C 59.09%, H 6.61%, N 11.49%, O 13.12%, Cl 9.69%
Properties: White crystalline solid from water/isopropanol, mp 178.5-179.5°. pKa 7.4.
Melting point: mp 178.5-179.5°
pKa: pKa 7.4
 
Derivative Type: 3S-Form
Properties: [a]D25 -14° (c = 0.19 in methanol).
Optical Rotation: [a]D25 -14° (c = 0.19 in methanol)
 
Derivative Type: 3R-Form
Properties: [a]D24 +16° (c = 0.34 in methanol).
Optical Rotation: [a]D24 +16° (c = 0.34 in methanol)
 
Therap-Cat: Antiemetic.
Keywords: Antiemetic; Serotonin Receptor Antagonist.